Tăng cường khả năng di chuyển và hiệu quả chống u của tế bào CAR T bằng cách chặn sự định vị của Protein Kinase A

Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849

Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 95ra73, 10.1126/scitranslmed.3002842

Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134

Gilham, 2012, CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe, Trends Mol Med, 18, 377, 10.1016/j.molmed.2012.04.009

Lipowska-Bhalla, 2012, Targeted immunotherapy of cancer with CAR T cells: achievements and challenges, Cancer Immunol Immunother, 61, 953, 10.1007/s00262-012-1254-0

Gajewski, 2007, Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment, Clin Cancer Res, 13, 5256, 10.1158/1078-0432.CCR-07-0892

Baitsch, 2012, The three main stumbling blocks for anticancer T cells, Trends Immunol, 33, 364, 10.1016/j.it.2012.02.006

Gajewski, 2013, Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment, Curr Opin Immunol, 25, 268, 10.1016/j.coi.2013.02.009

Wang, 2013, Overcoming intrinsic inhibitory pathways to augment the antineoplastic activity of adoptively transferred T cells: Re-tuning your CAR before hitting a rocky road, Oncoimmunology, 2, e26492, 10.4161/onci.26492

Moon, 2014, Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors, Clin Cancer Res, 20, 4262, 10.1158/1078-0432.CCR-13-2627

Gessi, 2011, Adenosine receptors and cancer, Biochim Biophys Acta, 1808, 1400, 10.1016/j.bbamem.2010.09.020

Kirschner, 2009, Mouse models of altered protein kinase A signaling, Endocr Relat Cancer, 16, 773, 10.1677/ERC-09-0068

Lo, 2015, Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells, Cancer Res, 75, 2800, 10.1158/0008-5472.CAN-14-3041

John, 2013, Blockade of PD-1 immunosuppression boosts CAR T-cell therapy, Oncoimmunology, 2, e26286, 10.4161/onci.26286

Sitkovsky, 2008, Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia, Clin Cancer Res, 14, 5947, 10.1158/1078-0432.CCR-08-0229

Carlos, 2001, Leukocyte recruitment at sites of tumor: dissonant orchestration, J Leukoc Biol, 70, 171, 10.1189/jlb.70.2.171

Lorenowicz, 2007, cAMP signaling in leukocyte transendothelial migration, Arterioscler Thromb Vasc Biol, 27, 1014, 10.1161/ATVBAHA.106.132282

Tasken, 2006, The molecular machinery for cAMP-dependent immunomodulation in T-cells, Biochem Soc Trans, 34, 476, 10.1042/BST0340476

Mosenden, 2011, Cyclic AMP-mediated immune regulation–overview of mechanisms of action in T cells, Cell Signal, 23, 1009, 10.1016/j.cellsig.2010.11.018

Brudvik, 2012, Modulation of T cell immune functions by the prostaglandin E(2)–cAMP pathway in chronic inflammatory states, Br J Pharmacol, 166, 411, 10.1111/j.1476-5381.2011.01800.x

Manz, 2015, Small molecule inhibition of Csk alters affinity recognition by T cells, Elife, 4

Clegg, 1987, Inhibition of intracellular cAMP-dependent protein kinase using mutant genes of the regulatory type I subunit, J Biol Chem, 262, 13111, 10.1016/S0021-9258(18)45175-7

Goldstein, 1997, Cyclic-AMP modulates downstream events in CD40-mediated signal transduction, but inhibition of protein kinase A has no direct effect on CD40 signaling, J Immunol, 159, 5871, 10.4049/jimmunol.159.12.5871

Raskovalova, 2007, Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling, Cancer Res, 67, 5949, 10.1158/0008-5472.CAN-06-4249

Su, 2008, Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression, Cancer Immunol Immunother, 57, 1611, 10.1007/s00262-008-0494-5

Su, 2011, Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes, Cancer Immunol Immunother, 60, 111, 10.1007/s00262-010-0924-z

Murray, 2008, Pharmacological PKA inhibition: all may not be what it seems, Sci Signal, 1, re4, 10.1126/scisignal.122re4

Beene, 2007, A-kinase anchoring proteins take shape, Curr Opin Cell Biol, 19, 192, 10.1016/j.ceb.2007.02.011

Jarnaess, 2007, Spatiotemporal control of cAMP signalling processes by anchored signalling complexes, Biochem Soc Trans, 35, 931, 10.1042/BST0350931

Ruppelt, 2007, Inhibition of T cell activation by cyclic adenosine 5′-monophosphate requires lipid raft targeting of protein kinase A type I by the A-kinase anchoring protein ezrin, J Immunol, 179, 5159, 10.4049/jimmunol.179.8.5159

Carlson, 2006, Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor, J Biol Chem, 281, 21535, 10.1074/jbc.M603223200

Dell'Acqua, 2006, Regulation of neuronal PKA signaling through AKAP targeting dynamics, Eur J Cell Biol, 85, 627, 10.1016/j.ejcb.2006.01.010

Mosenden, 2011, Mice with disrupted type I protein kinase A anchoring in T cells resist retrovirus-induced immunodeficiency, J Immunol, 186, 5119, 10.4049/jimmunol.1100003

Jarnaess, 2008, Dual specificity A-kinase anchoring proteins (AKAPs) contain an additional binding region that enhances targeting of protein kinase A type I, J Biol Chem, 283, 33708, 10.1074/jbc.M804807200

Riese, 2013, Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases, Cancer Res, 73, 3566, 10.1158/0008-5472.CAN-12-3874

Wang, 2014, Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity, Cancer Immunol Res, 2, 154, 10.1158/2326-6066.CIR-13-0027

Jackaman, 2003, IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2, J Immunol, 171, 5051, 10.4049/jimmunol.171.10.5051

Zhao, 2010, Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor, Cancer Res, 70, 9053, 10.1158/0008-5472.CAN-10-2880

Moon, 2011, Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor, Clin Cancer Res, 17, 4719, 10.1158/1078-0432.CCR-11-0351

Foster, 2008, Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor, J Immunother, 31, 500, 10.1097/CJI.0b013e318177092b

Lacuesta, 2006, Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor, J Immunother, 29, 250, 10.1097/01.cji.0000192104.24583.ca

Wang, 2010, Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells, Clin Cancer Res, 16, 164, 10.1158/1078-0432.CCR-09-1758

Dannenberg, 2003, Targeting cyclooxygenase-2 in human neoplasia: rationale and promise, Cancer Cell, 4, 431, 10.1016/S1535-6108(03)00310-6

Sitkovsky, 2004, Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors, Annu Rev Immunol, 22, 657, 10.1146/annurev.immunol.22.012703.104731

Brownlie, 2013, T cell receptor signalling networks: branched, diversified and bounded, Nat Rev Immunol, 13, 257, 10.1038/nri3403

Oberprieler, 2010, High-resolution mapping of prostaglandin E2-dependent signaling networks identifies a constitutively active PKA signaling node in CD8+CD45RO+ T cells, Blood, 116, 2253, 10.1182/blood-2010-01-266650

Moeller, 2005, Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection, Blood, 106, 2995, 10.1182/blood-2004-12-4906

Sommermeyer, 2016, Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo, Leukemia, 30, 492, 10.1038/leu.2015.247

Laudanna, 1997, Elevation of intracellular cAMP inhibits RhoA activation and integrin-dependent leukocyte adhesion induced by chemoattractants, J Biol Chem, 272, 24141, 10.1074/jbc.272.39.24141